AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 181 min read$BLSM

BlossomHill Therapeutics reports Q2 2026 net loss $23.8M, cash $95.4M; completed $168.3M IPO

BlossomHill Therapeutics reported a Q2 2026 net loss of $23.8M, or $8.75 per share, with $95.4M in cash. The company raised $168.3M in an IPO, funding operations into Q2 2028. Key developments include FDA Fast Track designation for BH-30643 and clinical progress for BH-30236 and BH-501284.

Original reporting
tradingview.com
Published Sep 18, 2026, 11:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BlossomHill Therapeutics reports Q2 2026 net loss $23.8M, cash $95.4M; completed $168.3M IPO — source image
Source · tradingview.com
Decision brief

The 30-second read

$BLSMNeutralMed
01

Why it matters

The disclosed financials and clinical milestones provide fresh data for valuation models.

02

Market read

New earnings and capital raise data create a fresh trading catalyst for BLSM.

03

What to watch

Fast Track designation for BH‑30643 could accelerate regulatory timeline, offsetting loss concerns.

Relevance 8/10Novelty 8/10Timing: post‑quarter earnings release

Background

BlossomHill Therapeutics filed an 8‑K reporting its Q2 2026 results and IPO details.

Company-level read

Ticker impact

$BLSMNeutralHigh confidence
Context

Q2 2026 net loss of $23.8M, cash $95.4M and $168.3M IPO proceeds disclosed in the 8‑K filing.

Expected impact

Potential short‑term volatility; investors may weigh loss against cash runway and FDA Fast Track designation.

Evidence & confidence

Biotech stocks often react to loss figures and cash runway; the Fast Track news adds upside bias.

Market effects

Sector

Highlights continued cash‑raising activity in early‑stage biotech and may influence peer valuations.

Regional

US biotech sector sees fresh capital inflow; no broader regional effect.

Global

Limited to biotech investors; no macro impact.

Counterpoint

What could challenge this read

The loss may be overstated risk; cash runway to 2028 could support a rally on clinical data.

Key entities

  • company
    BlossomHill Therapeutics

    Biotech firm developing oncology candidates.

Read at source← All news

Related articles

SEP 22
$AMRXMed

Biotech Stocks At 52-Week Highs - AMRX, BLSM, NEOG. NEO

Amneal Pharmaceuticals (AMRX) rose 7% to $21.17 after FDA approval for a generic Lanreotide injection. BlossomHill Therapeutics (BLSM) climbed 6% to $27.99 following positive Phase 1/2 study results. Neogen (NEOG) increased 2% to $13.34 after reporting Q4 revenue of $225M. NeoGenomics (NEO) hit a 52-week high of $20.05 after announcing Medicare and Medicaid coverage for its RaDaR ST test.

rttnews.com2 min
SEP 18
$BLSMMed

BlossomHill Therapeutics, Inc. (BLSM): Results of Operations and Financial Condition

BlossomHill Therapeutics, Inc. (BLSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-p

SEC EDGAR 8-K2 min
SEP 16
$BLSMMedAI 8/10

BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update

BlossomHill Therapeutics (BLSM) shares rose 4.4% premarket after presenting Phase 1/2 trial data for BH-30643 in EGFR C797S-positive NSCLC, showing 45% response rate. The drug has FDA Fast Track designation. Guggenheim initiated coverage with a Buy rating and $30 target. The stock is above its IPO price but below its 52-week high.

yahoo.com2 min